Tvardi Therapeutics, Inc. (TVRD) Institutional Ownership

Ownership Summary

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) currently has 73 active institutional owners and shareholders as of today (September 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• These investors collectively held 28.0% of the company's total shares outstanding in September 2025, up from 20.8% in June 2025.
• In percentage terms, this reflects as a holdings change of 37.14% quarter on quarter, and an increase of 4.29% year over year.
• A review of institutional activity for Tvardi Therapeutics shows 48 of 73 filers increasing their positions, while 6 reduced their stake, and 19 remained unchanged.
• This class of investors increased its holdings in Tvardi Therapeutics to 2.63Mn shares for the 13F-cycle ending September 2025, up by 711.83K shares quarter on quarter, and up 2.26Mn shares year over year.
• Slate Path Capital LP's holding of 704.12K shares as of September 30, 2025 makes it the primary institutional investor in Tvardi Therapeutics, owning 7.51% of the stock.
• Among the most significant buyers of Tvardi Therapeutics during September 2025 were Vestal Point Capital, LP (167.00K), Invesco Ltd. (82.61K), FMR LLC (82.22K), Parkman Healthcare Partners LLC (65.00K), BlackRock, Inc. (62.04K).
• Leading sellers of Tvardi Therapeutics stock in September 2025 included BANK OF AMERICA CORP /DE/ (1.72K), MORGAN STANLEY (1.11K), CITIGROUP INC (1.08K), RENAISSANCE TECHNOLOGIES LLC (1.06K), NEW YORK STATE COMMON RETIREMENT FUND (1.00K).
• The top 10 institutional holders of Tvardi Therapeutics for the quarter ending September 2025 included Slate Path Capital LP (704.12K), VANGUARD GROUP INC (419.17K), BlackRock, Inc. (329.91K), 683 Capital Management, LLC (176.03K), Vestal Point Capital, LP (167.00K), GEODE CAPITAL MANAGEMENT, LLC (147.92K), Invesco Ltd. (82.61K), FMR LLC (82.22K), Parkman Healthcare Partners LLC (65.00K), STATE STREET CORP (62.86K).